Male and female participants ≥ 18 years of age with advanced or metastatic cancers
Conditions
Brief summary
Incidence of AEs, SAEs, AEs meeting protocol defined DLT criteria, AEs leading to discontinuation and death
Detailed description
Summary measures of PK parameters of BMS-986340 administered as monotherapy and in combination with nivolumab or docetaxel, Incidence of anti-drug antibodies to BMS-986340 when BMS-986340 is administered as monotherapy and in combination with nivolumab or docetaxel, ORR, DCR, DOR, and PFSR
Interventions
DRUGDocetaxel-Ebewe
DRUG10 mg/ml
DRUGAnti-CCR8 NF mAb
DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of AEs, SAEs, AEs meeting protocol defined DLT criteria, AEs leading to discontinuation and death | — |
Secondary
| Measure | Time frame |
|---|---|
| Summary measures of PK parameters of BMS-986340 administered as monotherapy and in combination with nivolumab or docetaxel, Incidence of anti-drug antibodies to BMS-986340 when BMS-986340 is administered as monotherapy and in combination with nivolumab or docetaxel, ORR, DCR, DOR, and PFSR | — |
Countries
Germany, Italy, Spain
Outcome results
None listed